Preclinical studies indicate that targeting polo-like kinase 1 (PLK-1) with selective inhibitors like BI-2536, alone or combined with MDM2 inhibition, effectively reduces cell viability, restores p53 function, and induces apoptosis in adrenocortical carcinoma (ACC) cells, suggesting a promising therapeutic approach for ACC (58, 59). This evidence concerns the gene PLK1 and adrenal cortex carcinoma.